Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CTOR |
---|---|---|
09:32 ET | 376 | 1.64 |
09:34 ET | 2966 | 1.6116 |
09:39 ET | 1000 | 1.622 |
09:50 ET | 800 | 1.65 |
10:35 ET | 700 | 1.65 |
10:44 ET | 110 | 1.66 |
10:50 ET | 1113 | 1.65 |
10:55 ET | 351 | 1.64 |
10:57 ET | 109 | 1.645 |
11:04 ET | 500 | 1.63 |
11:15 ET | 575 | 1.63 |
11:18 ET | 1650 | 1.6201 |
11:22 ET | 350 | 1.6499 |
11:24 ET | 4500 | 1.65 |
11:42 ET | 16906 | 1.665 |
11:47 ET | 100 | 1.68 |
11:51 ET | 5100 | 1.68 |
11:54 ET | 800 | 1.66 |
12:20 ET | 150 | 1.698526 |
12:25 ET | 757 | 1.6601 |
12:27 ET | 100 | 1.66 |
12:41 ET | 100 | 1.67 |
12:45 ET | 100 | 1.67 |
12:52 ET | 400 | 1.66 |
12:57 ET | 110 | 1.68 |
01:06 ET | 2480 | 1.66 |
01:14 ET | 100 | 1.66 |
01:17 ET | 100 | 1.66 |
01:19 ET | 300 | 1.68 |
01:26 ET | 100 | 1.67 |
01:28 ET | 100 | 1.66 |
01:35 ET | 100 | 1.66 |
01:39 ET | 700 | 1.67 |
01:46 ET | 600 | 1.68 |
01:51 ET | 800 | 1.68 |
01:53 ET | 300 | 1.68 |
02:04 ET | 300 | 1.68 |
02:09 ET | 100 | 1.68 |
02:11 ET | 200 | 1.68 |
02:18 ET | 100 | 1.68 |
02:20 ET | 100 | 1.68 |
02:24 ET | 200 | 1.68 |
02:26 ET | 500 | 1.69 |
02:44 ET | 100 | 1.68 |
02:49 ET | 100 | 1.68 |
02:51 ET | 100 | 1.68 |
02:56 ET | 100 | 1.68 |
03:00 ET | 200 | 1.68 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Citius Oncology Inc | 120.5M | 6.9x | --- |
Fibrobiologics Inc | 120.2M | -3.4x | --- |
Nuvectis Pharma Inc | 120.1M | -5.0x | --- |
Invivyd Inc | 121.7M | -0.6x | --- |
Adicet Bio Inc | 117.8M | -0.6x | --- |
INmune Bio Inc | 123.1M | -3.1x | --- |
Citius Oncology, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on oncology products. Its LYMPHIR (denileukin diftitox-cxdl) is approved by United States Food and Drug Administration for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (a rare form of non-Hodgkin lymphoma) after at least one prior systemic therapy. LYMPHIR is a specially engineered IL-2- diphtheria toxin fusion protein made using recombinant DNA technology. It works by targeting cells that have IL-2 receptors with a toxin derived from diphtheria bacteria. It directly kills tumor cells by binding to the IL-2 receptors and internalizing the diphtheria toxin directly into the tumor cells, causing them to die. It boosts the body's immune response by reducing the number of regulatory T-cells (Tregs) that suppress the immune system, thereby enhancing the body's ability to fight the tumor.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $120.5M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 71.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $0.24 |
Book Value | $7.89 |
P/E Ratio | 6.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | 62.3x |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.